Tesla
TSLA
NVIDIA
NVDA
Palantir
PLTR
4
Apple
AAPL
5
Strategy
MSTR
US Stock MarketDetailed Quotes
URGN UroGen Pharma Ltd
- 9.920
- +0.100+1.02%
Close Mar 10 16:00 ET
457.26MMarket Cap-3.35P/E (TTM)
9.995High9.110Low461.73KVolume9.110Open9.820Pre Close4.47MTurnover1.25%Turnover RatioLossP/E (Static)46.09MShares20.70052wk High-51.94P/B366.97MFloat Cap9.03052wk Low--Dividend TTM36.99MShs Float69.568Historical High--Div YieldTTM9.01%Amplitude4.850Historical Low9.688Avg Price1Lot Size
UroGen Pharma Ltd Stock Forum
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102
UroGen's Major Pipeline Play: Revolutionary Cancer-Fighting Virus Acquisition Reshapes Growth Strategy
Breakthrough Bladder Cancer Treatment Achieves 83% Response Rate, FDA Decision Coming 2025
Clinical Trial Results: Cancer Drug Maintains Response for Nearly 4 Years, Surpassing Expectations
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
• Kaplan-Meier Estimate of Duration of Response at 12 Months in Patients Who Achieved a Complete Response at Three Months was 82.3% (95% CI, 75.9%, 87.1%)
• Side Effect Profile Consistent with Previous Clinical Trials of UGN-102
• UroGen will Host a Virt...
No comment yet